» Articles » PMID: 36375633

Efficacy of Novel SPAK Inhibitor ZT-1a Derivatives (1c, 1d, 1g & 1h) on Improving Post-stroke Neurological Outcome and Brain Lesion in Mice

Overview
Journal Neurochem Int
Specialties Chemistry
Neurology
Date 2022 Nov 14
PMID 36375633
Authors
Affiliations
Soon will be listed here.
Abstract

SPAK inhibitor ZT-1a was previously shown to be neuroprotective in murine ischemic stroke models. In this study, we further examined the efficacy of four ZT-1a derivatives (ZT-1c, -1d, -1g and -1h) on reducing stroke-induced sensorimotor function impairment and brain lesions. Vehicle control (Veh) or ZT-1 derivatives were administered via osmotic pump to adult C57BL/6J mice during 3-21 h post-stroke. Neurological behavior of these mice was assessed at days 1, 3, 5, and 7 post-stroke and MRI T2WI and DTI analysis was subsequently conducted in ex vivo brains. Veh-treated stroke mice displayed sensorimotor function deficits compared to Sham mice. In contrast, mice receiving ZT-1a derivatives displayed significantly lower neurological deficits at days 3-7 post-stroke (p < 0.05), with ZT-1a, ZT-1c and ZT-1d showing greater impact than ZT-1h and ZT-1g. ZT-1a treatment was the most effective in reducing brain lesion volume on T2WI and in preserving NeuN + neurons (p < 0.01), followed by ZT-1d > -1c > -1g > -1h. The Veh-treated stroke mice displayed white matter tissue injury, reflected by reduced fractional anisotropy (FA) or axial diffusivity (AD) values in external capsule, internal capsule and hippocampus. In contrast, only ZT-1a-as well as ZT-1c-treated stroke mice exhibited significantly higher FA and AD values. These findings demonstrate that post-stroke administration of SPAK inhibitor ZT-1a and its derivatives (ZT-1c and ZT-1d) is effective in protecting gray and white matter tissues in ischemic brains, showing a potential for ischemic stroke therapy development.

Citing Articles

Ion transporter cascade, reactive astrogliosis and cerebrovascular diseases.

Rahman M, Islam R, Bhuiyan M Front Pharmacol. 2024; 15:1374408.

PMID: 38659577 PMC: 11041382. DOI: 10.3389/fphar.2024.1374408.


Experimental Ischemic Stroke Induces Secondary Bihemispheric White Matter Degeneration and Long-Term Cognitive Impairment.

Liu R, Berry R, Wang L, Chaudhari K, Winters A, Sun Y Transl Stroke Res. 2024; .

PMID: 38488999 DOI: 10.1007/s12975-024-01241-0.


Cation-Chloride Cotransporters KCC2 and NKCC1 as Therapeutic Targets in Neurological and Neuropsychiatric Disorders.

Lam P, Newland J, Faull R, Kwakowsky A Molecules. 2023; 28(3).

PMID: 36771011 PMC: 9920462. DOI: 10.3390/molecules28031344.

References
1.
Tetko I, Gasteiger J, Todeschini R, Mauri A, Livingstone D, Ertl P . Virtual computational chemistry laboratory--design and description. J Comput Aided Mol Des. 2005; 19(6):453-63. DOI: 10.1007/s10822-005-8694-y. View

2.
Gagnon K, Delpire E . Molecular physiology of SPAK and OSR1: two Ste20-related protein kinases regulating ion transport. Physiol Rev. 2012; 92(4):1577-617. PMC: 4519243. DOI: 10.1152/physrev.00009.2012. View

3.
Huang H, Bhuiyan M, Jiang T, Song S, Shankar S, Taheri T . A Novel Na-K-Cl Cotransporter 1 Inhibitor STS66* Reduces Brain Damage in Mice After Ischemic Stroke. Stroke. 2019; 50(4):1021-1025. PMC: 6608592. DOI: 10.1161/STROKEAHA.118.024287. View

4.
Maier B, Desilles J, Mazighi M . Intracranial Hemorrhage After Reperfusion Therapies in Acute Ischemic Stroke Patients. Front Neurol. 2020; 11:599908. PMC: 7759548. DOI: 10.3389/fneur.2020.599908. View

5.
Smith E, Saver J, Cox M, Liang L, Matsouaka R, Xian Y . Increase in Endovascular Therapy in Get With The Guidelines-Stroke After the Publication of Pivotal Trials. Circulation. 2017; 136(24):2303-2310. DOI: 10.1161/CIRCULATIONAHA.117.031097. View